Tags

Type your tag names separated by a space and hit enter

Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Gynecol Endocrinol 2013; 29(4):375-9GE

Abstract

OBJECTIVE

To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients.

DESIGN

Controlled clinical study.

SETTING

PCOS patients in a clinical research environment.

PATIENTS

50 overweight PCOS patients were enrolled after informed consent.

INTERVENTIONS

All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.

MAIN OUTCOME MEASURES

Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.

RESULTS

After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.

CONCLUSIONS

MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.

Authors+Show Affiliations

Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy. paolo.artini@med.unipi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23336594

Citation

Artini, P G., et al. "Endocrine and Clinical Effects of Myo-inositol Administration in Polycystic Ovary Syndrome. a Randomized Study." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 29, no. 4, 2013, pp. 375-9.
Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375-9.
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013). Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 29(4), pp. 375-9. doi:10.3109/09513590.2012.743020.
Artini PG, et al. Endocrine and Clinical Effects of Myo-inositol Administration in Polycystic Ovary Syndrome. a Randomized Study. Gynecol Endocrinol. 2013;29(4):375-9. PubMed PMID: 23336594.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. AU - Artini,P G, AU - Di Berardino,O M, AU - Papini,F, AU - Genazzani,A D, AU - Simi,G, AU - Ruggiero,M, AU - Cela,V, Y1 - 2013/01/22/ PY - 2013/1/23/entrez PY - 2013/1/23/pubmed PY - 2013/8/31/medline SP - 375 EP - 9 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 29 IS - 4 N2 - OBJECTIVE: To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients. DESIGN: Controlled clinical study. SETTING: PCOS patients in a clinical research environment. PATIENTS: 50 overweight PCOS patients were enrolled after informed consent. INTERVENTIONS: All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed. MAIN OUTCOME MEASURES: Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio. RESULTS: After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid. CONCLUSIONS: MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/23336594/Endocrine_and_clinical_effects_of_myo_inositol_administration_in_polycystic_ovary_syndrome__A_randomized_study_ L2 - http://www.tandfonline.com/doi/full/10.3109/09513590.2012.743020 DB - PRIME DP - Unbound Medicine ER -